DOCSLIB.ORG

Single-Shot Ad26 Vaccine Protects Against SARS-Cov-2 in Rhesus Macaques W

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Single-Shot Ad26 Vaccine Protects Against SARS-Cov-2 in Rhesus Macaques W https://doi.org/10.1038/s41586-020-2607-z Accelerated Article Preview Single-shot Ad26 vaccine protects against W SARS-CoV-2 in rhesus macaques E VI Received: 20 June 2020 Noe B. Mercado, Roland Zahn, Frank Wegmann, Carolin Loos, Abishek Chandrashekar, Jingyou Yu, Jinyan Liu, Lauren Peter, Katherine McMahan, Lisa H. Tostanoski,E Xuan He, Accepted: 24 July 2020 David R. Martinez, Lucy Rutten, Rinke Bos, Danielle van Manen, Jort Vellinga, Jerome Custers, Accelerated Article Preview Published Johannes P. Langedijk, Ted Kwaks, Mark J. G. Bakkers, DavidR Zuijdgeest, online 30 July 2020 Sietske K. Rosendahl Huber, Caroline Atyeo, Stephanie Fischinger, John S. Burke, Jared Feldman, Blake M. Hauser, Timothy M. Caradonna,P Esther A. Bondzie, Gabriel Dagotto, Cite this article as: Mercado, N. B. et al. Makda S. Gebre, Emily Hoffman, Catherine Jacob-Dolan, Marinela Kirilova, Zhenfeng Li, Single-shot Ad26 vaccine protects against Zijin Lin, Shant H. Mahrokhian, Lori F. Maxfield, Felix Nampanya, Ramya Nityanandam, SARS-CoV-2 in rhesus macaques. Nature Joseph P. Nkolola, Shivani Patel, John D. Ventura,E Kaylee Verrington, Huahua Wan, https://doi.org/10.1038/s41586-020-2607-z Laurent Pessaint, Alex Van Ry, Kelvin Blade, Amanda Strasbaugh, Mehtap Cabus, (2020). Renita Brown, Anthony Cook, Serge Zouantchangadou,L Elyse Teow, Hanne Andersen, Mark G. Lewis, Yongfei Cai, Bing Chen, Aaron G. Schmidt, R. Keith Reeves, Ralph S. Baric, Douglas A. Lauffenburger, Galit Alter,C Paul Stoffels, Mathai Mammen, Johan Van Hoof, Hanneke Schuitemaker &T DanI H. Barouch This is a PDF fle of a peer-reviewed paper that has been accepted for publication. Although unedited,R the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. TheA text and fgures will undergo copyediting and a proof review before the paper is published in its fnal form. Please note that during the production process errorsD may be discovered which could afect the content, and all legal disclaimers Eapply. T A R E L E C C A Nature | www.nature.com Article Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques W 1,10 2,10 2,10 3,4,10 https://doi.org/10.1038/s41586-020-2607-z Noe B. Mercado , Roland Zahn , Frank Wegmann , Carolin Loos , Abishek 1,10 1,10 1,10 1,10 E1,10 Chandrashekar , Jingyou Yu , Jinyan Liu , Lauren Peter , Katherine McMahan , Received: 20 June 2020 Lisa H. Tostanoski1,10, Xuan He1,10, David R. Martinez5,10, Lucy Rutten2, Rinke Bos2I, Accepted: 24 July 2020 Danielle van Manen2, Jort Vellinga2, Jerome Custers2, Johannes P. Langedijk2, Ted Kwaks2, 2 2 2 V 3,6 Mark J. G. Bakkers , David Zuijdgeest , Sietske K. Rosendahl Huber , Caroline Atyeo , Published online: 30 July 2020 Stephanie Fischinger3,6, John S. Burke3, Jared Feldman3,6, Blake M. Hauser3,6, Timothy M. Caradonna3,6, Esther A. Bondzie1, Gabriel Dagotto1,6, MakdaE S. Gebre1,6, Emily Hoffman1, Catherine Jacob-Dolan1,6, Marinela Kirilova1, Zhenfeng Li1, Zijin Lin1, Shant H. Mahrokhian1, Lori F. Maxfield1, Felix Nampanya1, RamyaR Nityanandam1, Joseph P. Nkolola1, Shivani Patel1, John D. Ventura1, Kaylee Verrington1, Huahua Wan1, Laurent Pessaint7, Alex Van Ry7, Kelvin Blade7, AmandaP Strasbaugh7, Mehtap Cabus7, Renita Brown7, Anthony Cook7, Serge Zouantchangadou7, Elyse Teow7, Hanne Andersen7, Mark G. Lewis7, Yongfei Cai8, Bing Chen8,9, Aaron G. Schmidt3,6,9, R. Keith Reeves1, Ralph S. Baric5, Douglas A. Lauffenburger4, GalitE Alter3,9, Paul Stoffels2, Mathai Mammen2, Johan Van Hoof2, Hanneke SchuitemakerL2,11 & Dan H. Barouch 1,3,6,9,11 ✉ A safe and efective vaccine for severeC acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be requiredI to end the coronavirus disease 2019 (COVID-19) pandemic1–8. For global deploymentT and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efcacy of a single doseR of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in nonhuman primates. Fifty-two rhesus macaques wereA immunized with Ad26 vectors encoding S variants or sham control and were challenged with SARS-CoV-2 by the intranasal and intratracheal routes9,10. The optimal Ad26D vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs following ESARS-CoV-2 challenge. Vaccine-elicited neutralizing antibody titres correlated with protective efcacy, suggesting an immune correlate of protection. These data T demonstrate robust single-shot vaccine protection against SARS-CoV-2 in nonhuman A primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is R currently being evaluated in clinical trials. The rapid expansion of the COVID-19 pandemic has made the development mutations: (i) tissue plasminogen activator (tPA) leader sequence with of a SARS-CoV-2 vaccineE a global health and economic priority. Adenovirus full-length S (tPA.S)12, (ii) tPA leader sequence with full-length S with serotype 26 (Ad26) vectors11 encoding viral antigens have been shown to mutation of the furin cleavage site and two proline stabilizing mutations induce robust humoralL and cellular immune responses to various patho- (tPA.S.PP)13–15, (iii) wildtype leader sequence with native full-length S gens in both nonhuman primates and humans. In this study, we developed (S), (iv) wildtype leader sequence with S with deletion of the cytoplas- a series of Ad26E vectors encoding different variants of the SARS-CoV-2 spike mic tail (S.dCT)16, (v) tandem tPA and wildtype leader sequences with (S) protein and evaluated their immunogenicity and protective efficacy full-length S (tPA.WT.S)12, (vi) wildtype leader sequence with S with againstC SARS-CoV-2 challenge in rhesus macaques. deletion of the transmembrane region and cytoplasmic tail reflecting the soluble ectodomain, with mutation of the furin cleavage site, proline C stabilizing mutations, and a foldon trimerization domain (S.dTM.PP)15, Generation and Immunogenicity of Ad26 Vaccine and (vii) wildtype leader sequence with full-length S with mutation of A Candidates the furin cleavage site and proline stabilizing mutations (S.PP) (Fig. 1a). We produced seven Ad26 vectors expressing SARS-CoV-2 S variants that Western blot analyses confirmed S expression in cell lysates from all reflected different leader sequences, antigen forms, and stabilization vectors (Fig. 1b). 1Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 2Janssen Vaccines and Prevention BV, Leiden, Netherlands. 3Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. 4Massachusetts Institute of Technology, Cambridge, MA, USA. 5University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 6Harvard Medical School, Boston, MA, USA. 7Bioqual, Rockville, MD, USA. 8Children’s Hospital, Boston, MA, USA. 9Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA. 10These authors contributed equally: Noe B. Mercado, Roland Zahn, Frank Wegmann, Carolin Loos, Abishek Chandrashekar, Jingyou Yu, Jinyan Liu, Lauren Peter, Katherine McMahan, Lisa H. Tostanoski, Xuan He, David R. Martinez. 11These authors jointly supervised this work: Hanneke Schuitemaker, Dan H. Barouch. ✉e-mail: [email protected] Nature | www.nature.com | 1 Article We immunized 52 adult rhesus macaques, 6-12 years old, with controls, although protection was optimal with Ad26-S.PP (Fig. 4d). Ad26 vectors expressing tPA.S (N=4), tPA.S.PP (N=4), S (N=4), S.dCT All vaccinated animals showed no detectable infectious virus in NS by (N=4), tPA.WT.S (N=4), S.dTM.PP (N=6), S.PP (N=6), and sham controls PFU assays (Extended Data Fig. 5). (N=20). Animals received a single immunization of 1011 viral particles A comparison of peak viral loads in the vaccinated animals suggested (vp) Ad26 vectors by the intramuscular route without adjuvant at that protection in BAL was generally more robust than in NS (Fig. 5). The week 0. We observed RBD-specific binding antibodies by ELISA in 31 Ad26-S.PP vaccine provided complete protection in both the lower and of 32 vaccinated animals by week 2 and in all vaccinated animals by upper respiratory tract with the exception of one animal that showed week 4 (Fig. 2a). Neutralizing antibody (NAb) responses were assessed a low amount of virus in NS, and resulted in >3.2 and >3.9 log10 reducW- W using both a pseudovirus neutralization assay9,10,16 (Fig. 2b) and a live tions of median peak sgRNA in BAL and NS, respectively, as compared 9,10,17,18 virus neutralization assay (Fig. 2c). NAb titers as measured by with sham controls (P<0.0001 and P<0.0001, respectively,E two-sided E both assays were observed in the majority of vaccinated animals at Mann-Whitney tests) (Fig. 5). Among the 32 vaccinated macaques, 17 week 2 and generally increased by week 4. The Ad26-S.PP vaccine animals were completely protected and had no detectableI sgRNA in I elicited the highest pseudovirus NAb titers (median 408; range 208- BAL or NS following challenge, and 5 additional animalsV had no sgRNA V 643) and live virus NAb titers (median 113; range 53-233) at week 4 in BAL but showed some virus in NS. (P<0.05, two-sided Mann-Whitney tests). Pseudovirus NAb titers cor- related with both ELISA titers and live virus NAb titers (P<0.0001, E E R=0.8314 and P<0.0001, R=0.8427, respectively, two-sided Spearman Immune Correlates of Protection rank-correlation tests; Extended Data Fig. 1). Median NAb titers in the The size of this study and the variabilityR in outcomes with the differ- R Ad26-S.PP vaccinated macaques were 4-fold higher than median NAb ent vaccine constructs facilitated an immune correlates analysis.
Load more

Recommended publications
  • Plasma Proteomics of COVID-19 Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics
    Plasma Proteomics of COVID-19 Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics Jason Roh Harvard Medical School Robert Kitchen Harvard Medical School https://orcid.org/0000-0003-1443-8559 J Sawalla Guseh Massachusetts General Hospital Jenna McNeill Massachusetts General Hospital Malika Aid Beth Israel Deaconess Medical Center BIDMC Amanda Martinot Tufts University https://orcid.org/0000-0001-6237-6191 Andy Yu Massachusetts General Hospital Colin Platt Massachusetts General Hospital James Rhee Massachusetts General Hospital Brittany Weber Brigham and Women's Hospital Lena Trager Massachusetts General Hospital Margaret Hastings Massachusetts General Hospital Sarah Ducat Tufts University https://orcid.org/0000-0002-5285-7642 Peng Xia Massachusetts General Hospital Claire Castro Massachusetts General Hospital Bjarni Atlason Page 1/26 Massachusetts General Hospital Timothy Churchill Massachusetts General Hospital Marcelo Di Carli Brigham and Women's Hospital Patrick Ellinor The Broad Institute of MIT and Harvard https://orcid.org/0000-0002-2067-0533 Dan Barouch Beth Israel Deaconess Medical Center https://orcid.org/0000-0001-5127-4659 Jennifer Ho Massachusetts General Hospital Anthony Rosenzweig ( [email protected] ) Massachusetts General Hospital Article Keywords: COVID-19, cardiovascular complications, disease severity, mortality Posted Date: June 8th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-539712/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/26 Abstract Cardiovascular complications are common in COVID-19 and strongly associated with disease severity and mortality. However, the mechanisms driving cardiac injury and failure in COVID-19 are largely unknown. We performed plasma proteomics on 80 COVID-19 patients and controls, grouped according to disease severity and cardiac involvement.
    [Show full text]
  • Arxiv:2003.13670V4 [Cs.CY] 3 Apr 2020 IV Program
    Anonymous Collocation Discovery: Harnessing Privacy to Tame the Coronavirus∗ Ran Canetti† Ari Trachtenberg‡ Mayank Varia§ Boston University April 7, 2020 Abstract Successful containment of the Coronavirus pandemic rests on the ability to quickly and reliably identify those who have been in close proximity to a contagious individual. Existing tools for doing so rely on the collection of exact location information of individuals over lengthy time periods, and combining this information with other personal information. This unprecedented encroachment on individual privacy at national scales has created an outcry and risks rejection of these tools. We propose an alternative: an extremely simple scheme for providing fine-grained and timely alerts to users who have been in the close vicinity of an infected individual. Crucially, this is done while preserving the anonymity of all individuals, and without collecting or storing any personal information or location history. Our approach is based on using short-range communication mechanisms, like Bluetooth, that are available in all modern cell phones. It can be deployed with very little infrastructure, and incurs a relatively low false-positive rate compared to other collocation methods. We also describe a number of extensions and tradeoffs. We believe that the privacy guarantees provided by the scheme will encourage quick and broad voluntary adoption. When combined with sufficient testing capacity and existing best practices from healthcare professionals, we hope that this may significantly reduce the infection rate. To avoid confusion, we stress that this work does not propose any direct medical treatment. arXiv:2003.13670v4 [cs.CY] 3 Apr 2020 Rather, it proposes a way to pool together information from the community in order to help (a) direct medical personnel in how to best allocate and use testing resources, and (b) direct individuals as to when to get tested and self-quarantine.
    [Show full text]
  • Southern California Public Radio- FCC Quarterly Programming Report July 1- September 30,2016 KPCC-KUOR-KJAI-KVLA-K227BX-K210AD S
    Southern California Public Radio- FCC Quarterly Programming Report July 1- September 30,2016 KPCC-KUOR-KJAI-KVLA-K227BX-K210AD START TIME DURATION ISSUE TITLE AND NARRATIVE 7/1/2016 Take Two: Border Patrol: Yesterday, for the first time, the US Border patrol released the conclusions of that panel's investigations into four deadly shootings. Libby Denkmann spoke with LA Times national security correspondent, Brian Bennett, 9:07 9:00 Foreign News for more. Take Two: Social Media Accounts: A proposal floated by US Customs and Border Control would ask people to voluntarily tell border agents everything about their social media accounts and screen names. Russell Brandom reporter for The Verge, spoke 9:16 7:00 Foreign News to Libby Denkmann about it. Law & Order/Courts/Polic Take Two: Use of Force: One year ago, the LAPD began training officers to use de-escalation techniques. How are they working 9:23 8:00 e out? Maria Haberfeld, professor of police science at John Jay College of Criminal Justice spoke to A Martinez about it. Take Two: OC Refugee dinner: After 16 hours without food and water, one refugee family will break their Ramadan fast with mostly strangers. They are living in Orange County after years of going through the refugee process to enter the United States. 9:34 4:10 Orange County Nuran Alteir reports. Take Two: Road to Rio: A Martinez speaks with Desiree Linden, who will be running the women's marathon event for the US in 9:38 7:00 Sports this year's Olympics. Take Two: LA's best Hot dog: We here at Take Two were curious to know: what’s are our listeners' favorite LA hot dog? They tweeted and facebooked us with their most adored dogs, and Producers Francine Rios, Lori Galarreta and host Libby Denkmann 9:45 6:10 Arts And Culture hit the town for a Take Two taste test.
    [Show full text]
  • Croi 2021 Program Committee
    General Information CONTENTS WELCOME . 2 General Information General Information OVERVIEW . 2 CONTINUING MEDICAL EDUCATION . 3 CONFERENCE SUPPORT . 4 VIRTUAL PLATFORM . 5 ON-DEMAND CONTENT AND WEBCASTS . 5 CONFERENCE SCHEDULE AT A GLANCE . 6 PRECONFERENCE SESSIONS . 9 LIVE PLENARY, ORAL, AND INTERACTIVE SESSIONS, AND ON-DEMAND SYMPOSIA BY DAY . 11 SCIENCE SPOTLIGHTS™ . 47 SCIENCE SPOTLIGHT™ SESSIONS BY CATEGORY . 109 CROI FOUNDATION . 112 IAS–USA . 112 CROI 2021 PROGRAM COMMITTEE . 113 Scientific Program Committee . 113 Community Liaison Subcommittee . 113 Former Members . 113 EXTERNAL REVIEWERS . .114 SCHOLARSHIP AWARDEES . 114 AFFILIATED OR PROXIMATE ACTIVITIES . 114 EMBARGO POLICIES AND SOCIAL MEDIA . 115 CONFERENCE ETIQUETTE . 115 ABSTRACT PROCESS Scientific Categories . 116 Abstract Content . 117 Presenter Responsibilities . 117 Abstract Review Process . 117 Statistics for Abstracts . 117 Abstracts Related to SARS-CoV-2 and Special Study Populations . 117. INDEX OF SPECIAL STUDY POPULATIONS . 118 INDEX OF PRESENTING AUTHORS . .122 . Version 9 .0 | Last Update on March 8, 2021 Printed in the United States of America . © Copyright 2021 CROI Foundation/IAS–USA . All rights reserved . ISBN #978-1-7320053-4-1 vCROI 2021 1 General Information WELCOME TO vCROI 2021 Welcome to vCROI 2021! The COVID-19 pandemic has changed the world for all of us in so many ways . Over the past year, we have had to put some of our HIV research on hold, learned to do our research in different ways using different tools, to communicate with each other in virtual formats, and to apply the many lessons in HIV research, care, and community advocacy to addressing the COVID-19 pandemic . Scientists and community stakeholders who have long been engaged in the endeavor to end the epidemic of HIV have pivoted to support and inform the unprecedented progress made in battle against SARS-CoV-2 .
    [Show full text]
  • CELEBRATION of SCIENCE
    CELEBRATION of SCIENCE COVID Lessons Learned: Scientific and Community Impact 72ND MEETING OF THE MGH SCIENTIFIC ADVISORY COMMITTEE Wednesday, April 7 & Thursday, April 8, 2021 Table of Contents 2–3 90–229 Meeting Agenda Department Reports 4 90 Anesthesia, Critical Care and P ain Medicine Martin Research Prizes 94 Cancer Center 5 98 The Consortia for Improving Medicine with Innovation Howard M. Goodman Fellowship & Technology 6–7 102 Dermatology SAC Membership 106 Emergency Medicine 110 Medicine 8–9 122 Molecular Biology ECOR Membership 126 Neurology 10–61 132 Neurosurgery MGRI Executive Report 136 Nursing 140 Obstetrics and Gynecology 62–69 148 Ophthalmology Programmatic Report 154 Oral and Maxillofacial 62 Center for Diversity Surgery and Inclusion (CDI) 158 Orthopaedics 64 Center for Faculty 168 Otolaryngology, Head and Development (CFD) Neck Surgery 176 Pathology 70–89 180 Pediatrics Thematic Center Report 194 Psychiatry 70 Center for Computational 198 Radiation Oncology and Integrative Biology 204 Radiology 74 Center for Genomic 208 Ragon Institute of MGH, Medicine MIT & Harvard 78 Center for Regenerative 210 Surgery Medicine 220 Urology 82 Center for Systems Biology 86 Wellman Center for Photomedicine Front cover photo thanks to Dylan Parsons, BS, Ragon Institute of MGH, MIT and Harvard (dylanparsonsphotography.com) Celebration of Science 3 Agenda Wednesday, April 7, 2021 11:00 AM – 1:00 PM Virtual Poster Session 2:00 – 5:00 PM Celebration Of Science Welcome and Opening Remarks Peter L. Slavin, MD, President, MGH ECOR Report David
    [Show full text]
  • At Least 18 Killed in Myanmar As Police Open Fire at Protests
    P2JW060000-5-A00100-17FFFF5178F ADVERTISEMENT Real value is morethan just apricetag. Learn moreonpage B10. ***** MONDAY,MARCH 1, 2021 ~VOL. CCLXXVII NO.48 WSJ.com HHHH $4.00 Last week: DJIA 30932.37 g 561.95 1.8% NASDAQ 13192.35 g 4.9% STOXX 600 404.99 g 2.4% 10-YR. TREASURY g 1 2/32 , yield 1.459% OIL $61.50 À $2.24 EURO $1.2074 YEN 106.56 Tehran What’s News Rejects EU Call Business&Finance For Talks urope is buying elec- Etric vehicles at arecord pace and has overtaken With U.S. China as the world’sbiggest EV market, as consumers are encouraged by govern- Iran’s push for easing ment subsidies and dozens of sanctions imperils of newcarsand hybrids. A1 hopes for revival of Jane Fraser takesover as Citigroup’sCEO with agoal of 2015 nuclear accord simplifying the giant bank at atime when it is struggling Iran rejected aEuropean to keep up with rivals. B1 Union offer to hold direct nu- February’s government- clear talks with the U.S. in the bond rout has rattled in- coming days,risking renewed vestor certainty that ul- tension between Tehran and tralow long-term interest Western capitals. rates are here to stay. B1 Herbalife plans to over- By Laurence Norman haul its board as Icahn in Brussels and winds down his involvement Michael R. Gordon with the company and it REUTERS in Washington Protesterstakecoverinaclash with riotpoliceinYangon on Sunday. Security forces openedfireoncrowdsinseveral cities. looks to burnish itsstanding Senior Western diplomats with other investors. B1 said Iran’s response doesn’t Berkshire posted a big- quash the Biden administra- ger quarterly profit, with At Least18Killed in Myanmar tion’shopes of reviving diplo- Buffett using his annual matic effortstorestorethe 2015 letter to explain a recent nuclear deal, struck between surge in stock buybacks.
    [Show full text]
  • Speakers' Biographies
    Speakers’ Biographies Bruce D. Walker Dr. Bruce D. Walker is the Director of the Ragon Institute of MGH, MIT and Harvard, a Professor of Medicine at Harvard Medical School, a Professor of Practice at MIT and a Howard Hughes Medical Institute Investigator. In addition to his clinical duties as a board certified Infectious Disease specialist, his research focuses on cellular immune responses in chronic viral infections with a particular focus on HIV. He leads an international translational clinical and basic science research effort to understand how some rare people who are infected with HIV, but have never been treated, can fight the virus with their immune system. Dr. Walker is also an Adjunct Professor at the Nelson Mandela School of Medicine in Durban, South Africa. There he collaborates with the Doris Duke Medical Research Institute at the University of KwaZulu-Natal and serves as a Principal Investigator in the HIV Pathogenesis Program, an initiative to study the evolution of the HIV and the immune responses effective in controlling this virus, as well as to contribute to training African scientists. He is a member of the Steering Committee for the KwaZulu-Natal Research Institute for TB and HIV (K-RITH), a 10-year initiative funded by HHMI to build a state of the art TB-HIV research facility at the heart of these dual epidemics in South Africa. Dr. Walker is also a member of the American Academy of Arts and Sciences, American Society for Clinical Investigation (ASCI), the American Association of Physicians (AAP), and the Institute of Medicine (IOM) of the National Academy of Sciences.
    [Show full text]
  • AAI LOOKS BACK 4 Fink Named Next Editor-In-Chief of the JI 6 Focus on Public Affairs: ■ AAI Honors Reps
    In This Issue… 2 Call for 2013 AAI Award Applications 3 AAI Embarking on 100th Anniversary Celebration AAI LOOKS BACK 4 Fink Named Next Editor-in-Chief of The JI 6 Focus on Public Affairs: ■ AAI Honors Reps. Van Hollen, Bilbray ■ Sequestration: Potential Impact Estimated ■ NIH Proceeds Cautiously Pending 2013 Budget ■ NCATS, CAN Panels Hold First Meetings ■ Bill to Ban Great Ape Research Remains Pending ■ NIAID Director Fauci Visits AAI Council 10 Members in the News: ■ Dan Barouch ■ Mary Disis ■ Tina Garza ■ Mario Santiago 14 In Memoriam: ■ Stanley Nathenson ■ Bernardetta Nardelli 16 AAI Looks Back: Immunologists American Expeditionary Forces field hospital inside ruins of church During World War I France, ca. 1918 (Library of Congress, Prints and Photographs Division) 24 AAI Outreach Program Update 26 AAI Welcomes Immunologists during the First World War: New Members One Soldier-Scientist’s Experience 34 Grant & Award Deadlines Stanhope Bayne-Jones (AAI 1917, 17th President 1930–31) 36 Meetings Calendar See page 16 >ÊvÀÊÓä£ÎÊÜ>À`Ê««V>Ìà Deadline: January 9, 2013 Applications are invited for the following AAI Travel Awards and Grants, which annually foster the promise and professional development of early- and mid-career investigators, including underrepresented minority scientists and trainees. NEW—AAI Trainee Poster Award Lustgarten-eBioscience Memorial Award This award provides up to $500 travel reimbursement to AAI trainee Established to honor the memory of AAI member Dr. Joseph Lustgarten, members (students and postdoctoral fellows) whose first-author this award is intended to advance the career of a mid-career scientist abstracts submitted to the AAI annual meeting are selected for who attends the AAI annual meeting and presents an outstanding poster sessions only and found to be exceptional by the AAI Abstract abstract specifically in the area of immune regulation.
    [Show full text]
  • COVID-19: Correlates of Protection
    COVID-19: Correlates of Protection Workshop hosted by the Clinical Development & Operations and Enabling Sciences SWAT Teams Thursday, November 19, 2020 Agenda Time (CET) Topic Speaker(s) 15:00 – 15:05 Welcome & Meeting Objectives Peter Dull, Ivana Knezevic Session 1: Evidence for Existence of an Immune Correlate for Covid-19 15:05 – 15:20 Correlates of Vaccine-Inducted Immunity – An Overview Stanley Plotkin 15:20 – 15:40 SARS-CoV-2 immunity overview and risk factors for re-infection Florian Krammer 15:40 – 15:55 PK/PD Considerations for SARS-CoV-2 Neutralizing Antibodies Andrew Charles Adams 15:55 – 16:10 Non-human primate (NHP) passive transfer and vaccine studies Dan Barouch 16:10 – 16:50 Panel Discussion Moderated by Karen Makar Session 2: Operational, Statistical and Regulatory Considerations for Covid-19 Immune Correlates 16:50 – 17:00 Opportunities for CoP Identification from Ongoing Phase III VE Studies Kristen Earle 17:00 – 17:15 Regulatory Perspective: Approach to Acceptance of CoP for Licensure Daniel Brasseur 17:15 – 17:25 COVID-19 Immunoassay Platform Overview Richard Koup Development of the COVID-19 Research Standards and 17:25 – 17:35 Valentina Bernasconi Global Immunoassay Network 17:35 – 17:50 Statistical Approaches for Assessment of Immune Correlates of Protection Peter Gilbert 17:50 – 18:25 Panel Discussion Moderated by Peter Dull 18:25 – 18:30 Wrap Up & Next Steps Paul Kristiansen, Jakob Cramer Privileged and confidential 2 Welcome & Meeting Objectives Peter Dull Deputy Director, Integrated Clinical Vaccine Development (Bill & Melinda Gates Foundation) Ivana Knezevic Group Lead, Norms and Standards for Biologicals (WHO) 3 Context for today’s workshop • Recent positive results from large Covid-19 vaccine efficacy studies is great news but we need multiple licensed products to have the necessary near-term global impact • Complexities for operational pathways for next vaccine registration highlights the urgent need to accelerate progress toward identification of an immune correlate of protection.
    [Show full text]
  • COVID -19 the First 365 Days
    COVID -19 The First 365 Days www.legalgraphics.net Days since first Year 1 of COVID-19 sign of virus Pennsylvania 26 North Carolina 24 Wyoming Madagascar Massachusetts 49 Ecuador South Carolina 32 Kyrgyzstan Countries Affected COVID-19 Events Philippines Feb. 18, 2020 New Hamshire 25 North Dakota Montserrat Zimbabwe 56 62 Macau Nepal Illinois Ireland 31 Barbados El Salvador Washington 53 Italy Russia Romania Georgia 28 Missouri Nebraska Bolivia 13 15 Country Name California Worldwide New Mexico Montana New Caledonia Papau Number of days Coronavirus Deaths Austria 19 24 Kansas 23 13 Gambia Mauritius Taiwan Hong Kong Malaysia Sri Lanka India UK Netherlands New York 19 New Jersey 17 Tennessee 25 Minnesota Arizona Connecticut 14 Turkey Michigan Mississippi 21 Maine 20 or since first sign of virus over 2,000 Nicaragua Cape Verde Wisconsin 13 South Korea Vietnam Australia Cambodia UAE Spain Switzerland Pakistan Oregon 24 Florida 31 Colorado 21 Maryland 25 Kentucky 19 Utah Virginia Vermont 26 Ohio 14 South Dakota Delaware 13 Idaho 12 Montenegro Bermuda # Number of countries East Timor reporting on same day China France Thailand Japan US Singapore Canada Germany Finland Sweden Belgium Egypt Iran Israel Iraq Brazil Mexico Rhode Island 27 Texas 29 Nevada 27 Hawaii 17 Indiana 17 Oklahoma 15 Iowa Lousiana 13 St. Vincent Arkansas Alaska 15 Alabama 22 St. Maarten Djibouti West Virginia 6 (symbol is linked to Uganda France ? page with more detail) 11 5 4 8 3 20 9 7 6 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 Indonesia South Africa Bangladesh US States Affected Nov.
    [Show full text]
  • Passive Transfer of Vaccine-Elicited Antibodies Protects Against SIV in Rhesus Macaques
    Article Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques Graphical Abstract Authors Galit Alter, Wen-Han Yu, Abishek Chandrashekar, ..., Lars Hangartner, Rafick-Pierre Sekaly, Dan H. Barouch Correspondence [email protected] In Brief Alter et al. demonstrate that vaccine- elicited antiviral antibodies can partially protect subjects from viral challenge in a non-human primate model of HIV infection. To demonstrate this proof of concept, the authors purify and transfer polyclonal IgG from vaccinated macaques showing a putative protective antibody signature to naive individuals. The signature, defined by systems serology, includes multiple antibody functions in the absence of broadly neutralizing antibodies. Highlights d We defined a putative protective SIV signature based on multiple antibody functions d Passive transfer of IgG from vaccinated macaques partially protected against SIV d These data demonstrate protective efficacy of vaccine- elicited antibodies in macaques Alter et al., 2020, Cell 183, 185–196 October 1, 2020 ª 2020 Elsevier Inc. https://doi.org/10.1016/j.cell.2020.08.033 ll ll Article Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques Galit Alter,1 Wen-Han Yu,1 Abishek Chandrashekar,2 Erica N. Borducchi,2 Khader Ghneim,3 Ashish Sharma,3 Rebecca Nedellec,4 Katherine R. McKenney,4 Caitlyn Linde,1 Thomas Broge,1 Todd J. Suscovich,1 Tom Linnekin,1 Peter Abbink,2 Noe B. Mercado,2 Joseph P. Nkolola,2 Katherine McMahan,2 Esther A. Bondzie,2 Venous Hamza,2 Lauren Peter,2 Nicole Kordana,2 Shant Mahrokhian,2 Michael S. Seaman,2 Wenjun Li,5 Mark G.
    [Show full text]
  • MIT Faculty Newsletter, Vol. XXXII No. 5, May/June 2020
    Massachusetts Vol. XXXII No. 5 Institute of May/June 2020 Technology MITFaculty http://web.mit.edu/fnl Newsletter in this issue we offer extensive responses to the killing of George Floyd, beginning with the Editorial and “Heartsick. Anguished. Enraged.” (below) and continuing through page 15; Faculty Chair Rick Danheiser’s “ ‘May You Live in Interesting Times’: The Year in Review” (page 22); and “On the Risks and Benefits of New International Engagements,” (page 24). See the new Aron Bernstein Memorial Page or visit our website. George Floyd Memorial, Minneapolis Interview with Heartsick. Editorial Ragon Institute Anguished. I. Challenging Systemic Racism at MIT Director Dr. Bruce Enraged. II. Greetings to our Graduates Walker in the Year of the Pandemic Helen Elaine Lee THE FOLLOWING INTERVIEW by HERE WE GO AGAIN with the grief Challenging Systemic Racism at MIT Faculty Newsletter Editorial Board Chair and outrage of being black in America. FOLLOWING THE KILLING OF Jonathan Alan King (JAK) with Dr. Bruce This time, we’re trying to survive two George Floyd by a white policeman on Walker (BW) was held on May 18, 2020. pandemics. With Covid, our communi- May 25, protests erupted across the ties are suffering disproportionate sick- nation against the grotesque wrongs of JAK: You’re part of the Ragon Institute and ness and death borne of longstanding anti-black racism and its long, tenacious the Institute for Medical Engineering and inequality, and enduring exploitation as hold on the American social structure. In Science [IMES] as well as the “essential” workers with no choice but to this hopeful moment fraught with possi- Massachusetts Consortium on Pathogen show up and risk exposure to do the work bilities, it is only right that MIT aims for Readiness.
    [Show full text]